New England Peptide Ranks First in Unbiased Covance Study for Quality, Customer Service


Boston, MA, April 25, 2007 – Researchers seeking the industry’s highest-quality peptides as well as customer service can turn definitively to New England Peptide, LLC (NEP).

In a recent peptide quality validation study conducted by Covance Research Products, NEP outperformed eight other peptide providers.

The Peptide Comparison Study evaluated the performance of nine peptide providers across key product and service quality criteria. Each company synthesized the same peptide sequence for the production of custom polyclonal antibodies. The resulting antibody was analyzed for mean antibody titer, determined by the Enzyme-Linked ImmunoSorbent Assay (ELISA) on the associated serum.

The peptide NEP produced for the study generated an antibody with an ELISA titer twice that of the closest competitor for all bleeds analyzed. The study also ranked NEP first in customer service among the nine companies.

“The study provides concrete data that distinguishes NEP in the industry,” says Dave Robinson, NEP’s CEO. “Since drug discovery project success is unquestionably linked to the quality of the active ingredient, NEP welcomed this opportunity to compare quality and service with others in the market. The results speak for themselves.”

New England Peptide (www.nepeptide.com) designs and manufactures peptide and antibody products for drug discovery organizations worldwide. Headquartered in Gardner, Mass., and founded in 1998, the company specializes in custom peptide synthesis and polyclonal antibody production.

#

 

http://www.prweb.com/releases/2007/04/prweb521020.htm 

Testimonials

"THANKS AGAIN for all the intellectual support that NEP has provided to us over the last year. My colleagues have been overwhelmingly impressed with the quality of service and level of thought that you have put into researching and thinking about our particular peptide and antibody production needs. The level of scholarship went well beyond what we expected from any peptide and antibody company, and was crucial in shaping our decisions. It has truly been a pleasure corresponding with you."
Cliff N. PhD - Lawrence Berkeley National Laboratory